Figure 2.
Protection of bone marrow–liver–thymus (BLT) humanized mice from vaginal human immunodeficiency virus type 1 (HIV-1) strain JR-CSF challenge. Ten microliters of a saline solution of the small-molecule CD4-mimetic compound (CD4mc) JP-III-48 at the indicated concentrations was applied intravaginally to female BLT humanized mice. A, JP-III-48 and the HIV-1JR-CSF challenge virus were mixed and incubated at room temperature for 30 minutes before intravaginal application. B, JP-III-48 was applied to the vaginal tract first, and 30 minutes later, mice were challenged vaginally with 10 μL of an HIV-1JR-CSF suspension. The percentage of infected mice is shown; n values denote the number of mice per group. The inset in each panel shows the average level of viremia in the infected mice treated with different concentrations of CD4mc; n values denote the number of infected mice.